We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Cinven

News List

Lonza Finalizes Divestment of Specialty Ingredients Business contractpharma
July 05, 2021
The agreement with Bain Capital and Cinven was previously announced in February.
Lonza to Divest Specialty Ingredients Biz contractpharma
February 10, 2021
Lonza has entered into a definitive agreement with Bain Capital and Cinven to to sell its Specialty Ingredients business and operations for an enterprise value of CHF 4.2 billion.
Bain Capital, Cinven to acquire Lonza Specialty Ingredients for $4.7 billion expresspharma
February 09, 2021
Bain Capital and Cinven are acquiring Lonza’s Specialty Ingredients division in a deal worth $4.7 billion, the Swiss contract drug maker said.